Novo Nordisk A S (NVO) SEC Filing 20-F Annual report for the fiscal year ending Thursday, December 31, 2020

Novo Nordisk A S

CIK: 353278 Ticker: NVO

View differences made from one year to another to evaluate Novo Nordisk A S's financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 20-F Annual Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Novo Nordisk A S.


Assess how Novo Nordisk A S's management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Novo Nordisk A S's Definitive Proxy Statement (Form DEF 14A) filed after their 2021 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors


Ticker: NVO
CIK: 353278
Form Type: 20-F Annual Report
Accession Number: 0001628280-21-001364
Submitted to the SEC: Wed Feb 03 2021 2:34:50 PM EST
Accepted by the SEC: Wed Feb 03 2021
Period: Thursday, December 31, 2020
Industry: Pharmaceutical Preparations

External Resources:
Stock Quote
Social Media

Bookmark the Permalink: